A Agilent Technologies Inc.

Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance

(NYSE: A) today announced the release of its new , representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent’s industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications.

In modern gas chromatography/mass spectrometry (GC/MS) workflows, GC/MS columns are often subjected to complex matrices and chemically active analytes that require reporting at trace levels. Under these conditions, maintaining the data quality needed to meet regulatory targets or other analytical requirements necessitates more frequent column changes, source cleaning, and potential sample re-runs, which decreases laboratory efficiency and increases costs.

Agilent J&W GC/MS 5Q columns provide exceptional peak symmetry for active analytes and set a new industry standard for minimal column bleed, enabling high sensitivity, maintaining accuracy and mass spectral fidelity, and accurate quantitation for the most challenging trace-level analytes. Additionally, these new GC/MS columns feature faster conditioning and are especially resistant to conditions that can shorten column life. Agilent J&W GC/MS 5Q columns enhance system performance in particularly difficult conditions, such as the use of hydrogen as a carrier gas, and in environmental workflows targeting emerging analytes of interest, where exceptional sensitivity and column durability are critical.

“This launch marks one of our most significant advancements in GC/MS column technology. The new J&W 5Q GC/MS columns are engineered to meet the rigorous demands of modern analytical laboratories,” said David Edwards, vice president and general manager of Agilent’s Chemistries Division. “By reducing the frequency of column changes and enhancing system performance, these columns not only improve data quality but also significantly boost laboratory efficiency and reduce operational costs.”

“Eagerly anticipated by our customers, this GC/MS column innovation underscores Agilent’s commitment to providing cutting-edge solutions that empower scientists to achieve their analytical goals with greater ease and reliability,” Edwards added.

Available in a range of dimensions, the Agilent J&W 5Q GC/MS columns extend the analytical options available to labs across a wide sector of markets and applications, including PFAS testing in environmental samples, analysis of residual pesticides in food, and more. Their enhanced performance strengthens Agilent’s position as a premium provider of solutions that push the boundaries of analytical methodology, allowing users of industry-leading Agilent GC/MS systems to extract even greater performance and value from their instruments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the . Follow Agilent on and .

EN
15/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch